Core Insights - Alnylam has marked a significant milestone with the one-year anniversary of AMVUTTRA's approval in the U.S. for patients with ATTR cardiomyopathy, indicating a new era of growth for the company [2] - The introduction of ONPATTRO in 2018 established a new class of RNAi therapeutics, providing transformative options for patients with hereditary ATTR amyloidosis with polyneuropathy [2][3] - The company is experiencing strong adoption of AMVUTTRA, particularly in the ATTR cardiomyopathy population, which is more prevalent than hereditary ATTR polyneuropathy [3] Company Strategy - Alnylam is investing in advanced capabilities aimed at enabling earlier diagnosis, better coordinated care, and improved long-term outcomes for patients [4] - The strategic focus is to lead with scientific innovation, target untreated patients or those progressing on stabilizers, and deliver a durable impact [4] - The company is advancing its next-generation TTR therapy, nucresiran, which has the potential to enhance treatment outcomes further [3]

Alnylam Pharmaceuticals Conference Call Summary Company Overview - **Company**: Alnylam Pharmaceuticals (NasdaqGS:ALNY) - **Focus**: Development of transformative therapies for patients with ATTR amyloidosis, particularly through RNAi therapeutics Key Industry Insights - **Market Dynamics**: The ATTR-CM (cardiomyopathy) treatment category is significantly underserved, with an estimated 200,000 patients in the U.S., of which over 80% remain untreated [14][12] - **Growth Trajectory**: The U.S. treatment category grew 56% annually in 2023 and 2024, accelerating to 77% in 2025 with the introduction of AMVUTTRA [12][12] - **Future Projections**: By 2030, the company anticipates treating up to 75,000 patients in the U.S. for ATTR-CM, positioning AMVUTTRA as a revenue leader in the TTR market [48][54] Core Company Highlights - **Product Launches**: AMVUTTRA was launched in 2022 for hereditary ATTR amyloidosis and expanded to ATTR cardiomyopathy in 2025, marking a pivotal growth milestone [2][3] - **Revenue Growth**: The TTR franchise revenues more than doubled in 2025 compared to 2024, with guidance for 2026 indicating an 83% growth at the midpoint, projecting revenues between $4.4 billion and $4.7 billion [3][8] - **Patient Access**: Approximately 90% of patients have secured first-line access to AMVUTTRA, with most paying zero out-of-pocket costs [8][62] Competitive Landscape - **Market Share**: AMVUTTRA has maintained about 70% share of new starts and over 80% of the total market share in the TTR silencer class, despite competition [30][34] - **Combination Therapy**: The potential for dual mechanism treatment strategies is highlighted, especially with the anticipated genericization of stabilizers like tafamidis [39][36] Clinical Value Proposition - **Clinical Outcomes**: Vutrisiran, a next-generation therapy, has shown a nearly 40% reduction in all-cause mortality in the HELIOS-B trial, with significant improvements in quality of life and reduction of gastrointestinal symptoms [23][24][29] - **Dosing Convenience**: Vutrisiran's quarterly dosing schedule enhances patient adherence and persistence, achieving over 90% adherence over two years [27][29] Strategic Initiatives - **Awareness and Diagnosis**: The company is investing in AI-enabled diagnostic technologies and partnerships to improve early diagnosis and care coordination for ATTR-CM patients [44][45] - **Patient Engagement**: Direct-to-consumer efforts are driving interest, with AMVUTTRA becoming the most requested therapy among patients [43][49] Future Outlook - **Sustained Growth**: Alnylam aims to continue expanding its prescriber base and maximizing adherence, with a focus on driving category growth and improving patient outcomes [50][49] - **Long-term Vision**: The company is committed to establishing leadership in the ATTR-CM market, leveraging its differentiated therapy and strong physician preference [48][47] Additional Insights - **Untapped Market Potential**: The company estimates that nearly 200,000 ATTR-CM patients exist in the U.S., with significant opportunities for treatment expansion as awareness and diagnosis improve [12][19] - **Collaboration Efforts**: Strategic collaborations with organizations like Viz.ai aim to enhance diagnostic pathways and improve patient care [44][68] This summary encapsulates the key points from the Alnylam Pharmaceuticals conference call, highlighting the company's strategic direction, market opportunities, and clinical advancements in the treatment of ATTR amyloidosis.

Core Insights - Codexis, Inc. reported a total revenue of $70.4 million for the fiscal year ended December 31, 2025, representing a 19% increase from $59.3 million in 2024, primarily driven by a Technology Transfer Agreement with Merck [10] - The company ended the year with $78.2 million in cash, cash equivalents, and short-term investments, providing a runway through 2027 [10] - The net loss for fiscal year 2025 was $44.0 million, or $0.50 per share, an improvement from a net loss of $65.3 million, or $0.89 per share, in 2024 [10] Financial Highlights - Fourth quarter revenue reached $38.9 million, an 81% increase compared to $21.5 million in Q4 2024, also attributed to the Merck agreement [10] - Product gross margin improved to 64% for the fiscal year 2025, up from 56% in 2024, due to a shift towards more profitable products [10] - Research & Development expenses for 2025 were $52.3 million, an increase from $46.3 million in 2024, driven by higher employee-related costs [10] Business Developments - Codexis engaged with over 40 companies on 55 potential opportunities, transitioning discussions from feasibility testing to broader contract negotiations [7] - The company signed a lease for a GMP facility, which will enable kilogram-scale manufacturing using the ECO Synthesis platform [7] - Codexis received ISO 9001 certification for its in-house manufacturing suite, supporting future commercial contracts [7] Upcoming Milestones - The company anticipates hosting presentations at the 2026 TIDES USA annual meeting to showcase data on stereoisomer configurations delivered via enzymatic synthesis [7] - Codexis plans to begin retrofit construction on its GMP facility in the second half of 2026, aiming for full production capability by the end of 2027 [7] - The company is seeking to sign a licensing deal with a major pharmaceutical company in the second half of 2026 [7]

Core Insights - Alnylam Pharmaceuticals reported fourth-quarter 2025 adjusted earnings of $1.25 per share, exceeding the Zacks Consensus Estimate of $1.16, compared to adjusted earnings of 6 cents in the same quarter last year [1] - Total revenues for the quarter were $1.10 billion, falling short of the Zacks Consensus Estimate of $1.14 billion, but representing an 85% year-over-year increase from $593.2 million [2] Financial Performance - Net product revenues reached $994.7 million, marking a 121% increase year over year, driven by strong demand for Amvuttra and other marketed drugs [3] - Net revenues from collaborators were $40.9 million, a 62% decrease from the previous year, primarily due to the absence of revenues from Novartis in the reported quarter [4] - Royalty revenues increased by 73% year over year to $61.4 million [5] Product Performance - Amvuttra generated sales of $826.6 million, up 189% year over year, although it missed the Zacks Consensus Estimate of $837.2 million [8] - Givlaari sales were $86.8 million, reflecting a 34% year-over-year increase and exceeding the Zacks Consensus Estimate of $79.7 million [9] - Oxlumo recorded sales of $49.6 million, a 14% increase year over year, but fell short of the Zacks Consensus Estimate of $55.2 million [9] Guidance and Future Outlook - For 2026, Alnylam expects net product revenues between $4.9 billion and $5.3 billion, indicating a year-over-year growth of 64-77% at constant exchange rates [17] - The company anticipates net revenues from collaborations and royalties to be in the range of $400 million to $500 million, with adjusted R&D and SG&A expenses projected between $2.7 billion and $2.8 billion [17] Overall Assessment - Alnylam's fourth-quarter results were mixed, with earnings surpassing estimates but revenues missing expectations, likely due to high market expectations rather than a decline in demand [18] - The significant year-over-year revenue growth was primarily driven by strong sales of Amvuttra, supported by recent label expansions [19]

Core Insights - Alnylam Pharmaceuticals achieved full-year GAAP profitability in 2025, driven by an 81% year-over-year growth in net product revenues [4] - The TTR franchise generated $858 million in Q4 2025, reflecting a 151% year-over-year increase, primarily due to the U.S. launch of Amvuttra for ATTR cardiomyopathy [4] - Amvuttra has nearly matched tafamidis in new treatment starts by its second full quarter post-launch, indicating a shift in prescribing dynamics [4] Strategic Performance and Platform Evolution - The company launched Cyrillis, a proprietary enzymatic ligation-based manufacturing platform aimed at expanding capacity and reducing costs for RNAi therapeutics [4] - Management attributes commercial success to broad first-line payer access, with over 90% of payers providing coverage without step-through requirements [4] 2026 Guidance and Long-term Strategic Goals - The 2026 TTR revenue guidance is projected between $4.4 billion and $4.7 billion, assuming continued category growth and a mid-single-digit net price decrease in the U.S. [8] - The 2030 strategy aims for a 25% revenue CAGR and 30% non-GAAP operating margins, supported by a pipeline of over 25 clinical programs [4][8] - Planned R&D investment will remain at approximately 30% of revenues to accelerate organic innovation and selectively access external technologies [8] Competitive Dynamics and Pricing Sustainability - Management anticipates a Q1 2026 revenue headwind due to pricing alignment in Germany and annual U.S. insurance reauthorizations [8] - International TTR revenue growth in 2026 is expected to align with 2025, moderated by lower launch pricing for cardiomyopathy in European markets [8] - Collaboration revenue is projected to decline by 38% in 2026 due to a one-time $300 million milestone from the zalesiran program not recurring [8]

Financial Data and Key Metrics Changes - Total global net product revenues for 2025 were nearly $3 billion, representing an 81% growth compared to 2024, driven by a more than doubling of revenue in the TTR franchise [25][26] - The company achieved GAAP profitability for the full year 2025 and expects to sustain profitability going forward [7][29] - Non-GAAP operating income for 2025 was $850 million, a $755 million increase compared to the previous year [28] Business Line Data and Key Metrics Changes - The TTR franchise generated $858 million in net revenues in Q4 2025, up 151% year-over-year [12] - The rare disease portfolio generated $136 million in net revenue in Q4, up 26% year-over-year [11] - GIVLAARI and OXLUMO together became a $500 million franchise in 2025, reflecting continued growth more than five years post-launch [11] Market Data and Key Metrics Changes - U.S. net revenues for the TTR franchise grew 20% compared to Q3 2025 and 222% compared to Q4 2024 [12] - International revenues grew 13% quarter-over-quarter and 47% year-over-year, indicating strong global momentum [14] - The company anticipates launching AMVUTTRA for ATTR cardiomyopathy in additional international markets throughout 2026 [14] Company Strategy and Development Direction - The company has set new five-year goals, Alnylam 2030, focusing on achieving global TTR leadership, sustainable innovation, and disciplined growth [8][9] - Plans include launching nucresiran in 2028 for polyneuropathy and 2030 for cardiomyopathy, with an aim for over 25% revenue CAGR through 2030 [10] - The company expects to invest approximately 30% of revenues in non-GAAP R&D to accelerate organic innovation and selectively access external innovation [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the size and growth of the ATTR-CM category, noting that the majority of patients remain untreated [15] - The early momentum of AMVUTTRA is encouraging, with strong customer demand and broad access expected to drive future growth [17] - Management highlighted the importance of improving diagnosis and treatment rates to expand the category further [18] Other Important Information - The company ended 2025 with cash, cash equivalents, and marketable securities of $2.9 billion, an increase from $2.7 billion at the end of 2024 [29] - Collaboration revenue for 2025 was $553 million, an 8% growth compared to 2024, including a significant milestone payment [26] Q&A Session Summary Question: Insights on new patient additions and first-line mix for patisiran versus tafamidis - Management expressed satisfaction with the AMVUTTRA launch and noted strong fundamentals supporting continued growth [41][43] Question: Addressing choppiness in scripts and pricing dynamics - Management indicated confidence in access and pricing, with a mid-single-digit net price decline expected in 2026 [49][61] Question: Seasonality effects in Q4 and potential tailwinds for Q1 2026 - Management acknowledged typical industry seasonality but emphasized that underlying momentum remains strong [53][54] Question: Gross to net pattern over 2026 - Management confirmed a gradual mid-single-digit net price decrease expected throughout the year [59][61] Question: External innovation strategy and potential partnerships - Management highlighted a focus on complementary technologies that enhance the existing portfolio and pipeline [66][98] Question: Impact of nucresiran on operating margins - Management anticipates significant positive margin impacts post-2030 if nucresiran demonstrates a best-in-class profile [70][71] Question: Updates on the Huntington's program and trial initiation - Management is optimistic about the Huntington's program and plans to accelerate it responsibly based on initial data [78][79] Question: Prioritization of ACVR1C asset in obesity pipeline - Management explained the prioritization based on preclinical data indicating ACVR1C's potential for greater efficacy compared to other targets [86][87]

Financial Data and Key Metrics Changes - Total global net product revenues for 2025 were nearly $3 billion, representing an 81% growth compared to 2024, driven by a more than doubling of revenue in the TTR franchise [24][25] - The company achieved GAAP profitability for the full year 2025 and expects to sustain profitability going forward [5][27] - Non-GAAP operating income for the full year was $850 million, a $755 million increase compared to the previous year [26] Business Line Data and Key Metrics Changes - The TTR franchise generated $858 million in net revenues in Q4 2025, up 151% year-over-year [11] - The rare disease portfolio generated $136 million in net revenue in Q4, reflecting a 26% increase compared to the same period last year [10] - GIVLAARI and OXLUMO together became a $500 million franchise in 2025, showing continued growth more than five years post-launch [10] Market Data and Key Metrics Changes - U.S. net revenues for the TTR franchise grew 20% compared to Q3 2025 and 222% compared to Q4 2024 [11] - International revenues grew 13% quarter-over-quarter and 47% year-over-year, indicating strong global momentum [12] - The company anticipates launching AMVUTTRA for ATTR cardiomyopathy in additional international markets throughout 2026 [12] Company Strategy and Development Direction - The company has set new five-year goals, Alnylam 2030, focusing on achieving global TTR leadership, sustainable innovation, and disciplined growth [6][9] - Plans include launching nucresiran in 2028 for polyneuropathy and 2030 for cardiomyopathy, with aspirations to deliver RNAi to 10 tissue types and expand the pipeline to over 40 clinical programs by 2030 [7][8] - The company aims for over 25% revenue CAGR through 2030 and a non-GAAP operating margin of approximately 30% [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the size and growth of the ATTR-CM category, noting that the majority of patients remain untreated [14] - The early momentum of AMVUTTRA is encouraging, with strong customer demand and broad access expected to drive growth [16] - The company is focused on improving diagnosis and treatment rates to expand the category further [17] Other Important Information - The company initiated three Phase 3 studies in 2025 and expanded its clinical pipeline with four proprietary CTAs [18] - The proprietary enzymatic ligation manufacturing platform, Syrelis, was launched to enhance capacity and reduce costs [20] - The company ended 2025 with cash, cash equivalents, and marketable securities of $2.9 billion, an increase from $2.7 billion at the end of 2024 [27] Q&A Session Summary Question: Can you comment on new patient adds and the mix of first-line for patisiran versus tafamidis switches? - Management highlighted strong AMVUTTRA launch momentum and improved first-line access, supporting confidence in 2026 guidance [38][41] Question: Can you speak to the choppiness in scripts for the first quarter and pricing dynamics? - Management noted that the majority of patients have first-line access and expect a mid-single-digit net price decline in 2026, which is integrated into their outlook [44][47] Question: Have you seen any seasonality during the fourth quarter? - Management acknowledged typical industry seasonality but emphasized that underlying momentum remains strong [50][51] Question: What is the rationale for prioritizing the ACVR1C asset over others in your pipeline? - Management indicated that ACVR1C appears to be a more potent target based on preclinical work and emerging data [81][85] Question: How should we think about the impact of nucresiran on operating margins once available? - Management expects nucresiran to have a best-in-class profile, potentially driving margins to the mid-40s post-2030 [68][69]

Core Insights - Argo Biopharmaceutical Co., Ltd. has initiated a global Phase 2b clinical trial for DII235 (BW-20829) in adults with elevated Lipoprotein (a) and Atherosclerotic Cardiovascular Disease, marking a significant advancement in its clinical pipeline [1][2] - The company will receive milestone payments from Novartis as part of their collaboration, which will support ongoing research and development of its siRNA portfolio [1] - BW-20829 is the sixth asset in Argo's pipeline to enter mid-stage global clinical development, highlighting the company's progress in RNAi therapeutics [1][3] Company Overview - Argo Biopharma is focused on developing next-generation RNAi therapeutics aimed at providing improved treatment options for various diseases, including cardiovascular diseases, viral infections, and metabolic conditions [3] - The company has established a diverse pipeline with six RNAi candidates currently in clinical development, showcasing its commitment to addressing unmet medical needs [3]

Core Viewpoint - Alnylam Pharmaceuticals has announced a new five-year strategy called "Alnylam 2030," aimed at scaling operations, achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility [1] Group 1: Strategic Focus - The strategy emphasizes achieving leadership in ATTR amyloidosis, a key area for the company [1] - The company aims to drive long-term growth through sustainable innovation, indicating a commitment to research and development [1] - Financial discipline and agility are highlighted as essential components for delivering exceptional results [1] Group 2: Financial Performance - Alnylam reported preliminary fourth quarter and full year 2025 global net product results, although specific figures were not disclosed in the announcement [1]

Summary of Alnylam Pharmaceuticals Conference Call Company Overview - Alnylam Pharmaceuticals is a leading RNA interference (RNAi) company, recognized for its innovative approach based on Nobel Prize-winning science. The company has successfully launched six marketed products and has a robust clinical pipeline with over 20 programs [2][4]. Key Focus Areas 1. **TTR Leadership**: - Alnylam aims to establish leadership in transthyretin (TTR) therapeutics, particularly with the launch of Amvuttra for cardiomyopathy. The company believes Amvuttra has the potential to become the standard of care [3][4]. - The next-generation program, Nucresiran, is expected to provide long-term durability for the TTR franchise, extending its impact into the 2040s [3]. 2. **Innovation and Pipeline Growth**: - Alnylam is focused on expanding its pipeline, which has the potential for three to four blockbuster medicines. The company emphasizes the high probability of success from its R&D efforts [3][4]. 3. **Financial Performance**: - The company is committed to disciplined capital allocation and aims to achieve sustainable non-GAAP profitability. Alnylam has seen growing revenues and is building a foundation for long-term growth [4][6]. Amvuttra Launch Insights - The launch of Amvuttra has exceeded expectations, with rapid access to 170 healthcare systems that account for 80% of TTR amyloidosis prescriptions. This early success allowed the company to raise revenue guidance [10][11]. - Patient volume demand has doubled, indicating strong market acceptance and effective execution by the commercial team [11][12]. - The company reports a balanced utilization of Amvuttra across both first-line and second-line treatment settings, with a significant share of first-line prescriptions [20][21]. Market Dynamics - There is a significant underdiagnosis issue in TTR cardiomyopathy, with only 20% of an estimated 150,000 patients in the US diagnosed. Alnylam sees opportunities for improved diagnosis rates due to advancements in diagnostic tools [31][32]. - The company is successfully penetrating community centers, which now contribute over half of its business, indicating a broad acceptance of Amvuttra [34]. Future Developments - Nucresiran is in two Phase 3 studies, with expectations for improved patient outcomes due to higher TTR knockdown rates and a more convenient dosing schedule [42][44]. - Alnylam is also advancing its pipeline in other areas, including Huntington's disease and hypertension, with promising early results [48][49]. Conclusion - Alnylam Pharmaceuticals is positioned for significant growth with its innovative RNAi therapeutics, particularly through the successful launch of Amvuttra and the upcoming Nucresiran. The company is focused on expanding its market presence, improving patient outcomes, and achieving financial sustainability [51].